Betsy Jenkins
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.
Tommaso Barba
Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.
Albert Garcia-Romeu
Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.
Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
Study investigates oral psilocybin effects on OCD symptoms and neural mechanisms mediating therapeutic effects. Clinical trial information available at NCT03356483.
Benjamin Kelmendi, Terence Ching
Study investigates oral psilocybin for cluster headaches. Subjects receive placebo, low or high dose psilocybin in 3 sessions, with headache diary monitoring. Second round may involve low or high dose
Emmanuelle Schindler
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.